Literature DB >> 15880762

Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons.

Wojciech Rzeski1, Tomasz Kocki, Anna Dybel, Katarzyna Wejksza, Barbara Zdzisińska, Martyna Kandefer-Szerszeń, Waldemar A Turski, Etsuo Okuno, Jan Albrecht.   

Abstract

The present study characterizes the synthesis of kynurenic acid (KYNA) from exogenously added kynurenine and its regulation by extrinsic factors, in cultured cerebral cortical neurons and, for comparison, in astrocytes incubated under identical conditions. The neuronal culture showed positive immunostaining for both kynurenic acid aminotransferase (KAT) isoforms I and II. Neurons synthesized KYNA at a rate about 2.3 times higher than astrocytes. Neuronal, but not astrocytic, KYNA synthesis was lowered approximately 30% by ionotropic glutamate receptor agonists [(R,S)-3-hydroxy-5-methoxyloxasole-4-propionic acid (AMPA; 100 microM) and N-methyl-D-aspartic acid (NMDA; 100 microM)] and depolarizing agents [KCl (50 mM) and 4-aminopyridine (4-AP; 10 microM)]. Neuronal and astrocytic synthesis alike were vulnerable to inhibition exerted by the aminotransferase inhibitor aminooxyacetic acid (AOAA), glutamate (IC50: 31 and 85 microM, respectively), substrates of the L-amino transport system [leucine (Leu); IC50: 19 and 42 microM, respectively] and 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid (BCH; IC50: 19 and 28 microM, respectively). Glutamine (Gln), which is a metabolic precursor of glutamate in astrocytes and L-system substrate in both cell types, inhibited KYNA synthesis both in neurons and in astrocytes (IC50: 268 and 318 microM, respectively). alpha-Ketoisocaproic acid (KIC), a Leu transamination product that is produced mainly in astrocytes and shuttled to neurons to modulate intraneuronal concentration of glutamate, stimulated KYNA synthesis in neurons but did not affect the synthesis in astrocytes. In conclusion, this study is the first to demonstrate active, regulation-prone KYNA synthesis in neurons. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880762     DOI: 10.1002/jnr.20505

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93).

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Etsuo Okuno; Martyna Kandefer-Szerszen; Jan Albrecht; Waldemar A Turski
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

2.  Quantitative Analysis of Kynurenine Aminotransferase II in the Adult Rat Brain Reveals High Expression in Proliferative Zones and Corpus Callosum.

Authors:  Chang Song; Sarah M Clark; Chloe N Vaughn; James D Nicholson; Kelley J Murphy; Ta-Chung M Mou; Robert Schwarcz; Gloria E Hoffman; Leonardo H Tonelli
Journal:  Neuroscience       Date:  2017-11-08       Impact factor: 3.590

3.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Authors:  Tomasz Kocki; Sebastian Wnuk; Renata Kloc; Janusz Kocki; Björn Owe-Larsson; Ewa M Urbanska
Journal:  J Neural Transm (Vienna)       Date:  2011-06-10       Impact factor: 3.575

Review 4.  Endogenous neuro-protectants in ammonia toxicity in the central nervous system: facts and hypotheses.

Authors:  Jan Albrecht; Michał Wegrzynowicz
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

5.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

Review 6.  Changing the face of kynurenines and neurotoxicity: therapeutic considerations.

Authors:  Zsuzsanna Bohár; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  Int J Mol Sci       Date:  2015-04-29       Impact factor: 5.923

7.  Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.

Authors:  Dániel Varga; Judit Herédi; Zita Kánvási; Marian Ruszka; Zsolt Kis; Etsuro Ono; Naoki Iwamori; Tokuko Iwamori; Hiroki Takakuwa; László Vécsei; József Toldi; Levente Gellért
Journal:  Front Behav Neurosci       Date:  2015-06-16       Impact factor: 3.558

Review 8.  Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?

Authors:  Aleksandra Ostapiuk; Ewa M Urbanska
Journal:  CNS Neurosci Ther       Date:  2021-12-03       Impact factor: 5.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.